Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
LGALS9 was initially thought to represent a pseudogene of galectin 9; however, this transcript has good exon-intron structure and encodes a predicted protein of the same size as and highly similar to galectin 9. Additionally we are shipping Lectin, Galactoside-Binding, Soluble, 9 Kits (62) and Lectin, Galactoside-Binding, Soluble, 9 Proteins (35) and many more products for this protein.
Showing 10 out of 195 products:
Mouse (Murine) Polyclonal LGALS9 Primary Antibody for CyTOF, FACS - ABIN4899254
Iqbal, Sampaio, Maione, Greco, Niki, Hirashima, Perretti, Cooper: Endogenous galectin-1 and acute inflammation: emerging notion of a galectin-9 pro-resolving effect. in The American journal of pathology 2011
Show all 4 Pubmed References
Human Polyclonal LGALS9 Primary Antibody for ELISA, WB - ABIN561667
Bellac, Coimbra, Simon, Imboden, Leib: Gene and protein expression of galectin-3 and galectin-9 in experimental pneumococcal meningitis. in Neurobiology of disease 2007
Show all 2 Pubmed References
Human Polyclonal LGALS9 Primary Antibody for IF (p), IHC (p) - ABIN733163
Daley, Mani, Mohan, Akkad, Ochi, Heindel, Lee, Zambirinis, Pandian, Savadkar, Torres-Hernandez, Nayak, Wang, Hundeyin, Diskin, Aykut, Werba, Barilla, Rodriguez, Chang, Gardner, Mahal, Ueberheide et al.: Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance. ... in Nature medicine 2017
in a model of experimental autoimmune encephalomyelitis, we show that an agonist of DR3 (show TNFRSF25 Antibodies) suppressed disease, correlating with expansion of CD4 (show CD4 Antibodies)+Foxp3 (show FOXP3 Antibodies)+ Tregs, and this protective effect was lost in Galectin-9-/- mice
Galectin 9 is a novel dectin 1 (show CLEC7A Antibodies) ligand in pancreatic ductal adenocarcinoma. Upon disruption of the dectin 1 (show CLEC7A Antibodies)-galectin 9 axis, CD4 (show CD4 Antibodies)(+) and CD8 (show CD8A Antibodies)(+) T cells, which are dispensable for PDA progression in hosts with an intact signaling axis, become reprogrammed into indispensable mediators of anti-tumor immunity.
The Gal-9/Tim-3 (show HAVCR2 Antibodies) signal is important for the regulation of decidua NK cells function, which is beneficial for the maintenance of a normal pregnancy.
These results indicate the possibility that cooperative binding of oligosaccharide and neighboring polypeptide structures of monoclonal IgE to galectin-9 affects the overall affinity and specificity of the IgE-lectin interaction.
galectin-9 functions as a novel alarmin by augmenting the inflammatory response in sepsis development during pulmonary F. novicida infection.
Gal-9 has a role in the maintenance of hepatic homeostasis and preventing liver ischemia-reperfusion injury
Gal-9, a natural TIM-3 (show HAVCR2 Antibodies) ligand, was produced primarily by and released from ischemia-reperfusion-stressed hepatocytes, both in vivo and in vitro.
Galectin-9 functions as an astrocyte-microglia communication signal and promotes cytokine production from microglia in a Tim-3 (show HAVCR2 Antibodies) independent manner.
galectin-9, in addition to being an effector molecule for regulatory T cells cells, acts synergistically with TGF-beta (show TGFB1 Antibodies) to enforce iTreg cell differentiation and maintenance.
Galectin-9 is a suppressor of T and B cells and predicts the immune modulatory potential of mesenchymal stromal cell preparations.
results suggested that Tim-3 (show HAVCR2 Antibodies) and Gal-9 could downregulate T cell inflammation in Osteoarthritis
Results show that human acute myeloid leukemia (show BCL11A Antibodies) (AML (show RUNX1 Antibodies)) cells possess a secretory pathway which leads to the production and release of soluble Tim-3 (show HAVCR2 Antibodies) and galectin-9. Both proteins prevent the activation of NK cells and impair their AML (show RUNX1 Antibodies) cell-killing activity.
Significantly elevated Gal-9 levels were found in both minimal-mild (I-II) and moderate-severe (III-IV) stages of endometriosis in comparison with healthy controls.
We investigated tumor-infiltrating CD4 (show CD4 Antibodies) and CD8 (show CD8A Antibodies) T cells and the expression of PD-L1 (show CD274 Antibodies), Galectin-9, and XAGE1 (show XAGE1A Antibodies) in stage I to IIIA lung adenocarcinomas using a tissue microarray to deduce their contribution to overall survival, and our data showed that PD-L1 (show CD274 Antibodies) expression was a positive indicator, whereas Galectin-9 and XAGE1 (show XAGE1A Antibodies) expression was negative.
Tim3 (show HAVCR2 Antibodies)/Gal-9 alleviates the inflammation of TAO patients via suppressing Akt (show AKT1 Antibodies)/NF-kappaB (show NFKB1 Antibodies) signaling pathway.
Low Gal-9 expression is associated with pancreatic and ampullary cancer.
X-ray structure of a protease-resistant mutant form of human galectin-9 having two carbohydrate recognition domains with a metal-binding site has been presented.
These findings may indicate that an increase in the Gal-9 level, a novel immune checkpoint molecule, can reflect immune-related adverse effects of various biotherapies.
Our data suggest a role of galectin-9 in regulating HIV transcription and viral production in vivo during therapy
The Tim-3 (show HAVCR2 Antibodies)/Gal-9 pathway might link disease progression with T cell exhaustion during bovine leukemia virus infection.
The relative abundance of PIBF (show PIBF1 Antibodies), LGALS1 (show LGALS1 Antibodies), LGALS3 (show LGALS2 Antibodies), LGALS3BP (show LGALS3BP Antibodies), and LGALS9 mRNA would display a differential expression pattern in the endometrium.
The galectins are a family of beta-galactoside-binding proteins implicated in modulating cell-cell and cell-matrix interactions. The protein encoded by this gene is an S-type lectin. It is overexpressed in Hodgkin's disease tissue and might participate in the interaction between the H&RS cells with their surrounding cells and might thus play a role in the pathogenesis of this disease and/or its associated immunodeficiency. Multiple alternatively spliced transcript variants have been found for this gene.
lectin, galactoside-binding, soluble, 9
, galactoside-binding soluble lectin 9
, galectin 9
, lectin, galactoside-binding, soluble, 9 (galectin 9)
, lectin, galactose binding, soluble 5
, tumor antigen HOM-HD-21
, urate transporter/channel protein
, 36 kDa beta-galactoside-binding lectin
, Lectin galactose binding soluble 9 (Galectin-9)
, Lectin, galactose binding, soluble 9 (Galectin-9)
, urate transporter/channel
, urate transporter
, urate transporter/channel protein, isoform (UATp,i)